Key Highlights

  • Third-quarter 2026 Revenue came to $411.5 million, a 23.1% (calculated) rise over the $334.2 million booked twelve months before.
  • Diagnostics sales reached $303.5 million, and the data and applications line grew to $108.1 million, a 32.9% (calculated) increase.
  • The net Deficit shrank to $14.9 million, equal to $0.08 a share, from $80.0 million, which equaled $0.46 a share, the year before.
  • Adjusted EBITDA came in at $25.6 million, up from $1.5 million in the comparable stretch last year.
  • Oncology tests climbed to around 101,500 from about 77,000, while cash and marketable securities were $854 million at quarter end.

Growth Accelerates Across Diagnostics and Data Applications Through September

Tempus AI (NASDAQ:TEM) released quarterly figures on Nov 2, 2026, covering the three months that finished Sep 30, 2026. Total revenue was $411.5 million, up from $334.2 million twelve months before. The Business blends lab testing with a sizable store of anonymized clinical and molecular records, applying artificial intelligence to cancer care and drug development.

Diagnostics revenue expanded to $303.5 million from $252.9 million. Management noted oncology sales rose 28% to roughly $173 million on a 32% increase in volume, and hereditary testing added about $111 million.

Data and applications sales hit $108.1 million, compared with $81.3 million earlier. The filing attributes $19.9 million of that gain to Insights data licensing, with $6.4 million coming from the Next product.

Equity Valuation Gains Narrow the Net Deficit While Adjusted EBITDA Turns Positive

The net loss was $14.9 million, equal to $0.08 a share, versus $80.0 million a year earlier. Other income totaled $47.1 million, mainly from a $44.0 million jump in unrealized Equity gains.

Operating loss narrowed to $56.9 million from $61.0 million, while non-GAAP adjusted EBITDA came to $25.6 million, up from $1.5 million.

Cost of revenues came to $144.8 million (calculated), which implies a gross Margin of roughly 64.8% (calculated), compared with 62.8% (calculated) previously. SG&A totals grew from $187.9 million to $231.9 million.

Licensing Deals With Pharma Partners and a Pending Diagnostics Purchase Frame the Forward View

Management reported a deal with a large drugmaker to license oncology datasets and models, worth as much as $138 million across five years. An Alzheimer's data tie-up adds $55 million more, lifting the expected extra revenue to $193 million.

The company also agreed in July to buy a molecular diagnostics business for an Enterprise value of $1.5 billion, or $16.25 per share, primarily through Class A equity. The chief executive indicated that regulatory review has been cleared, the target's Shareholder meeting is slated for Nov 30, with completion expected in the fourth quarter.

Management raised its 2026 revenue outlook and kept adjusted EBITDA near $65 million, though the new revenue range is not stated here.

The CFO stated that revised pricing for a tumor-only edition of a sequencing test that carries FDA approval begins on Jan 1, 2027, expected to add roughly $80 million of oncology revenue next year.

Reinvestment Plans and the Acquisition Close Set the Pace for Sustained Profitability

Tempus AI reported 23% revenue expansion and positive adjusted EBITDA, and Leadership still targets roughly 25% annual growth. Management earmarks two thirds of added Gross Profit for reinvestment and expects to absorb the target's losses after closing. Upcoming markers include a shareholder ballot on Nov 30 and the close during the final quarter of the year.